Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
(NY:
GSK
)
33.60
+0.17 (+0.51%)
Official Closing Price
Updated: 7:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
December 19, 2024
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.
Via
Benzinga
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
December 18, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations
October 30, 2024
The company said revenue from RSV vaccine tumbled 72%.
Via
Investor's Business Daily
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
December 18, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
December 18, 2024
Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.
Via
Investor's Business Daily
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
December 17, 2024
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025.
Via
Investor's Business Daily
What's Going On Moderna Stock On Monday?
December 16, 2024
Moderna faces index removal, stock plunge, vaccine challenges, and lawsuits, while focusing on R&D in oncology and rare diseases for future growth.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children
December 13, 2024
Lawyer files petition against polio vaccine, part of broader anti-vaccine campaign by Robert F. Kennedy Jr. and Aaron Siri, causing concerns for vaccine policies and pharma companies. Trump considering...
Via
Benzinga
Topics
Government
Exposures
Political
Product Safety
Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination
December 13, 2024
Avian flu continues to spread with cases in cats, horses, and humans. Scientists monitor wildlife infections. Vaccine development may face challenges.
Via
Benzinga
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
December 13, 2024
An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains.
Via
Benzinga
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
December 12, 2024
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.
Via
Benzinga
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
December 10, 2024
GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to Darzalex combo.
Via
Benzinga
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
December 09, 2024
From
GSK plc
Via
Business Wire
Oracle, Vertiv And A Health Care Stock On CNBC's 'Final Trades'
December 09, 2024
On CNBC's "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said Oracle is going to report a strong quarter.
Via
Benzinga
Bird Flu Found In Raw Milk Leads To Recall In California
November 26, 2024
Bird flu has been detected in a batch of raw milk sold in California and a voluntary recall of the milk has been issued at the request of the state's department of public health.
Via
Benzinga
Topics
Product Recall
Exposures
Legal
Product Safety
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
November 26, 2024
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.
Via
Benzinga
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
November 20, 2024
According to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry.
Via
Benzinga
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
November 19, 2024
GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its primary endpoint.
Via
Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
November 15, 2024
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.
Via
Benzinga
Exposures
Product Safety
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
November 14, 2024
GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.
Via
Benzinga
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
November 13, 2024
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.
Via
Benzinga
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
November 12, 2024
23andMe restructures, cutting 40% of its workforce and ending its therapeutic programs to save $35 million annually while exploring strategic alternatives.
Via
Benzinga
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
November 07, 2024
Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda.
Via
Benzinga
Topics
Government
Exposures
Political
Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing?
November 07, 2024
The company reported just $10 million in sales of its RSV vaccine, mResvia, widely missing expectations.
Via
Investor's Business Daily
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
October 30, 2024
GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines and HIV drugs show growth.
Via
Benzinga
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
October 24, 2024
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for millions at risk of serious disease.
Via
Benzinga
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
October 24, 2024
From
GSK plc
Via
Business Wire
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
October 23, 2024
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth.
Via
Benzinga
Exposures
Product Safety
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
October 21, 2024
Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.